NovaPump, a Jena, Germany-based developer and medical product manufacturer of percutaneous circulatory mechanical support systems (pMCS), closed a series A financing round.
Backers included a consortium of institutional and strategic investors.
The company intends to use the funds to develop the PERKAT™ products further to the first-in-man (FIM) trials.
The PERKAT RV device can be implanted to increase cardiac output (CO) of patients, who suffer from acute heart failure due to pulmonary embolism or myocardial infarction. The PERKAT MCS from NovaPump employs a self-expanding mechanism of the pump chamber. It is completely catheter-based, ECG controlled, and combines physiologic pulsatile mechanism and an automated pump mode. The heart pumps can be implanted under X-Ray control within a few minutes. They work in a pulsatile manner using ECG or pressure trigger to physiologically support the failing human heart. Post CE approval, the devices will be applied on current IABP (Intra Aortic Balloon Counterpulsation) technology, which is available for treatment in most heart centres worldwide today. The PERKAT heart pumps can further increase our therapeutic options with MCS in cardiogenic shock patients. The company is led by Ronald Reich, founder and CEO, and Prof Markus Ferrari (MD), co-founder and inventor of PERKAT.